We all need encouragement sometimes. What better way than to read some amazing stories of men and women who fought cancer and survived –even when the odds weren’t in their favor. Why do some patients beat the odds? Some go on experimental medicines that help them, but few others. Others take novel combinations of approved drugs that are too toxic for most to endure. The most mysterious cases of all are so-called spontaneous remissions, where tumors vanish without any treatment.
Charles Burrows experienced that in November 2005, when he was diagnosed with terminal liver cancer and given two months to live. Then, three months later, without any treatment, his tumor simply vanished. The case was so unusual that his doctors published it in a medical journal last year. Says Burrows, "I won a lottery, and I don't understand why."
While numerous explanations have been proposed for these mysterious remissions, one of the likeliest is that the body's immune system gets involved. A spontaneous remission is "either divine intervention or the immune system," says Jedd D. Wolchok, an oncologist at New York's Memorial Sloan-Kettering Cancer Center. To read more, go to: http://tinyurl.com/d4gh4w
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...